Table 4.
PFS in different subgroups.
| Subgroup | PFS (months), median (95% CI) |
|---|---|
| Metastatic sites | |
| Lymph nodes (n = 614) | 5.7 (5.3–6.2) |
| Bone (n = 401) | 5.6 (4.9–6.3) |
| Lung (n = 493) | 5.5 (4.9–6.1) |
| Liver (n = 363) | 4.2 (3.5–4.9) |
| Brain (n = 47) | 4.2 (3.3–5.8) |
| Number of metastasis | |
| 1 (n = 189) | 6.6 (5.2–7.4) |
| 2 (n = 329) | 5.6 (4.6–6.3) |
| ⩾3 (n = 481) | 5.4 (4.6–5.7) |
| ECOG performance status | |
| 0 (n = 275) | 5.7 (4.8–6.7) |
| 1 (n = 699) | 5.4 (4.8–6.0) |
| 2 (n = 29) | 5.9 (3.0–6.5) |
| Disease status | |
| Unresectable locally advanced (n = 205) | 6.4 (5.4–7.7) |
| Recurrent/metastatic (n = 818) | 5.4 (4.8–5.7) |
| Molecular subtype | |
| HR positive, HER2 negative (n = 302) | 5.7 (5.1–6.6) |
| HER2 positive (n = 376) | 5.4 (4.6–6.1) |
| Triple negative (n = 211) | 4.6 (3.7–5.5) |
| Menopause | |
| No (n = 384) | 5.7 (5.2–6.6) |
| Yes (n = 263) | 5.4 (4.6–5.9) |
| Age (years) | |
| <65 (n = 957) | 5.5 (5.2–5.9) |
| ⩾65 (n = 56) | 6.3 (3.4–8.4) |
| Chemotherapy regimens | |
| LBP alone (n = 52) | 4.5 (3.0–5.8) |
| LBP + paclitaxel (n = 125) | 8.0 (5.7–9.7) |
| LBP + docetaxel (n = 240) | 7.0 (6.0–8.0) |
| LBP + gemcitabine (n = 201) | 5.1 (4.0–5.9) |
| LBP + vinorelbine (n = 342) | 4.6 (3.7–5.5) |
ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; LBP, lobaplatin; PFS, progression-free survival.